Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 81 Florida 71 Illinois 50 Georgia 49 Arizona 37
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca105 Eli Lilly and Company89 Merck Sharp & Dohme LLC72 AbbVie68 Janssen Research & Development, LLC67 Clear sponsor filter
State
California81 Florida71 Illinois50 Georgia49 Arizona37
All 46 states
Target enrolment
to

Trials with a site in Georgia

49 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
NCT07772531Major Depressive Disorder
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-10-02
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-09-11
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
NCT07780383Alzheimer's Disease, Healthy Participants
DrugMoponetug
Bristol-Myers Squibb
Phase 1
84
California, Florida, Georgia
2026-08-21
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Active, closed
Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia
NCT07783373Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Observational
3,000
Georgia
2026-05-01
Recruiting
A Phase 1 Study of Navlimetostat Tablet Formulations
NCT07544628Healthy Participants
DrugNavlimetostat
Bristol-Myers Squibb
Phase 1
64
Georgia, Texas
2026-04-27
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kansas
2025-10-23
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
DrugKarXT
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Missouri, New York, Texas
2025-10-08
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Louisiana
2025-09-11
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
DrugsValproate·Lamotrigine·Lithium·KarXT
Bristol-Myers Squibb
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-07-18
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698Bipolar-I Disorder With Mania or Mania With Mixed Features
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Connecticut, Florida, Georgia, Illinois, New York, Ohio
2025-06-11
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306Anemia, Sickle Cell, Healthy Volunteers
DrugsFamotidine·Pantoprazole
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Active, closed
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 3
44
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-04-17
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886Alzheimer Disease, Early Onset
DrugMoponetug
Bristol-Myers Squibb
Phase 2
310
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Hampshire
2024-03-20
Active, closed
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Cardiomyopathy, Hypertrophic
DrugMavacamten
Bristol-Myers Squibb
Phase 4
63
California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah
2024-01-24
Active, closed
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134Melanoma
DrugsPhesgo·Relatlimab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941Sjögren's Syndrome
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
774
California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-09-11
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota
2023-01-12
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-01-12
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota
2023-01-10
Recruiting
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175Colitis, Ulcerative
DrugOzanimod
Bristol-Myers Squibb
Phase 2/3
120
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2022-05-30
Recruiting
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288Renal Allograft Recipients
DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus
Bristol-Myers Squibb
Phase 3
102
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts
2021-07-21
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2021-07-13
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 3
461
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Hampshire, Ohio
2019-11-05
Active, closed
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04099251Melanoma
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
790
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois
2019-10-28
Active, closed
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402Renal Cell Carcinoma
DrugsYervoy·Ipilimumab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
437
District of Columbia, Georgia, Massachusetts, Pennsylvania, South Carolina
2019-06-21
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
545
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana
2018-04-18
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
DrugsRelatlimab·Nivolumab
Bristol-Myers Squibb
Phase 2/3
714
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2018-04-11
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsYervoy·Ipilimumab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
1,314
Alaska, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2017-03-24
Active, closed
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512Multiple Myeloma
Bristol-Myers Squibb
Observational
2,555
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2012-06-13
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Georgia that also match the filters currently applied.

How many clinical trials are recruiting in Georgia?

27 of the 49 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Georgia), 49 studies
PhaseStudiesRecruitingShare
Phase 3281457.1%
Phase 2/37514.3%
Phase 25210.2%
Observational428.2%
Phase 1336.1%
Phase 1/2112%
Phase 4102%

Most active sponsors

Lead sponsors with the most studies (Georgia)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb4927
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.